--- title: "12 Health Care Stocks Moving In Tuesday's Intraday Session" description: "In Tuesday's intraday session, Polaryx Therapeutics (PLYX) saw a significant gain of 80.9%, reaching $4.36, with a market cap of $114 million. Other notable gainers included Baird Medical Investment (" type: "news" locale: "en" url: "https://longbridge.com/en/news/276150613.md" published_at: "2026-02-17T17:05:59.000Z" --- # 12 Health Care Stocks Moving In Tuesday's Intraday Session > In Tuesday's intraday session, Polaryx Therapeutics (PLYX) saw a significant gain of 80.9%, reaching $4.36, with a market cap of $114 million. Other notable gainers included Baird Medical Investment (BDMD) up 45.25%, Compass Pathways (CMPS) up 42.42%, and Masimo (MASI) up 34.4%. Conversely, Liminatus Pharma (LIMN) experienced the largest drop, falling 33.9% to $0.25. Other losers included Ocular Therapeutix (OCUL) down 24.84% and Mainz Biomed (MYNZ) down 22.67%. ### Gainers - **Polaryx Therapeutics** (NASDAQ:PLYX) shares increased by 80.9% to $4.36 during Tuesday's regular session. The company's market cap stands at $114.0 million. - **Baird Medical Investment** (NASDAQ:BDMD) stock increased by 45.25% to $1.12. The company's market cap stands at $28.2 million. - **Compass Pathways** (NASDAQ:CMPS) stock increased by 42.42% to $8.28. The market value of their outstanding shares is at $543.5 million. - **Masimo** (NASDAQ:MASI) shares moved upwards by 34.4% to $174.93. The market value of their outstanding shares is at $7.0 billion. - **Ensysce Biosciences** (NASDAQ:ENSC) shares increased by 28.68% to $0.56. The company's market cap stands at $1.5 million. - **Biodexa Pharmaceuticals** (NASDAQ:BDRX) stock increased by 21.75% to $1.31. ### Losers - **Liminatus Pharma** (NASDAQ:LIMN) shares fell 33.9% to $0.25 during Tuesday's regular session. The company's market cap stands at $10.1 million. - **Ocular Therapeutix** (NASDAQ:OCUL) shares decreased by 24.84% to $6.67. The market value of their outstanding shares is at $1.9 billion. - **Mainz Biomed** (NASDAQ:MYNZ) shares fell 22.67% to $0.62. The company's market cap stands at $6.8 million. - **Strata Skin Sciences** (NASDAQ:SSKN) stock fell 18.25% to $0.28. The market value of their outstanding shares is at $2.0 million. - **Quince Therapeutics** (NASDAQ:QNCX) shares declined by 15.06% to $0.17. The company's market cap stands at $11.1 million. - **Solid Biosciences** (NASDAQ:SLDB) shares fell 14.22% to $5.31. The market value of their outstanding shares is at $482.0 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/ This article was generated by Benzinga's automated content engine and reviewed by an editor. ### Related Stocks - [LIMN.US - Liminatus Pharma](https://longbridge.com/en/quote/LIMN.US.md) - [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/en/quote/IBBQ.US.md) - [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md) - [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md) - [MYNZ.US - Mainz Biomed NV](https://longbridge.com/en/quote/MYNZ.US.md) - [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md) - [PLYX.US - Polaryx Therapeutics](https://longbridge.com/en/quote/PLYX.US.md) - [IXJ.US - iShares Global Healthcare](https://longbridge.com/en/quote/IXJ.US.md) - [XHE.US - SPDR S&P Health Equip](https://longbridge.com/en/quote/XHE.US.md) - [MASI.US - Masimo](https://longbridge.com/en/quote/MASI.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | M&A News: Danaher Nears $10B Deal for Masimo | Danaher (DHR) is nearing a $9.9 billion acquisition of Masimo (MASI), reflecting a significant premium over Masimo's mar | [Link](https://longbridge.com/en/news/276103321.md) | | Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans | Polaryx Therapeutics (NASDAQ: PLYX) shares surged 46.06% to $3.52 following the selection of a research organization for | [Link](https://longbridge.com/en/news/276143893.md) | | Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial | Ocular Therapeutix announced that its experimental eye drug, Axpaxli, outperformed Regeneron's Eylea in a late-stage tri | [Link](https://longbridge.com/en/news/276119715.md) | | BridgeBio Pharma (BBIO) Receives a Buy from TD Cowen | TD Cowen analyst Tyler Van Buren has maintained a Buy rating on BridgeBio Pharma (BBIO) with a price target of $95.00. V | [Link](https://longbridge.com/en/news/275790948.md) | | GSA Capital Partners LLP Raises Stock Holdings in Merck & Co., Inc. $MRK | GSA Capital Partners LLP increased its stake in Merck & Co., Inc. by 107.8% in Q3, owning 24,809 shares valued at $2.08 | [Link](https://longbridge.com/en/news/276119315.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.